SITE010-0101

SITE010 (ESP) › SITE010-0101

SITE010-0101

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2026-01-01

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 196); relationship: NOT RELATED

moderate assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-25 (study day 172); relationship: NOT RELATED

mild assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 134); relationship: not assessed

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-05 (study day 122); relationship: not assessed

mild assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 121); relationship: not assessed

severe assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 47); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.